| Bioactivity | MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). This dual inhibition enhanced the overall antiviral potency and effect of MPI8. MPI8 can be used in clinical studies of COVID-19[1][2]. |
| CAS | 856242-63-2 |
| Formula | C32H48N4O7 |
| Molar Mass | 600.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ma X R, et al. MPI8 is potent against SARS‐CoV‐2 by inhibiting dually and selectively the SARS‐CoV‐2 main protease and the host cathepsin L[J]. ChemMedChem, 2022, 17(1): e202100456. [2]. Yang S, et al. Synthesis, crystal structure, structure− activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor[J]. Journal of medicinal chemistry, 2006, 49(16): 4971-4980. |